Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188702 · ClinicalTrials.gov registry record · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
A Phase 1 study of MTAP-deleted Solid Tumors, sponsored by Servier Bio-Innovation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 342
- Enrollment target
- 20
- Study locations
NCT06188702: Recruiting Phase 1 study of MTAP-deleted Solid Tumors, sponsored by Servier Bio-Innovation.
NCT06188702 is a Phase 1 study of MTAP-deleted Solid Tumors that is actively recruiting participants, run by Servier Bio-Innovation. The registered enrollment target is 342 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (470% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06188702, a Phase 1 study of MTAP-deleted Solid Tumors, is actively recruiting participants, sponsored by Servier Bio-Innovation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 342 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.
Primary Outcome
Phase 1 only
Conditions Studied
Interventions
- DRUG S095035
- DRUG TNG462
Study Locations (20)
Other
- Townsville University Hospital - Douglas
- Royal Hobart Hospital - Hobart
- University Hospital Rigshospitalet - Copenhagen
- Odense Universitets Hospital - Odense
- Institut Bergonié - Bordeaux
- Centre Georges-François Leclerc - Dijon
- Hôpital de la Timone (Marseille) - Marseille
- Institut Gustave Roussy - Paris
- Charite Universitatsmedizin - Berlin
California
- University of California Los Angeles - Los Angeles
- University of California, San Francisco (Ucsf) School of Medicine - San Francisco
Florida
- Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute - Lake Mary
Indiana
- Community Health Network - Indianapolis
Massachusetts
- Dana Farber Cancer Institue - Boston
North Carolina
- Duke University School of Medicine - Durham
Ohio
- Taylor Cancer Research Center - Maumee
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2031-10-31 |
| Phase | Phase 1 |
What NCT06188702 shows while recruiting
NCT06188702 is an interventional study that assigns participants to a tested intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (470% higher).
The record links to 1 condition, with MTAP-deleted Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which S095035 is the first listed.
NCT06188702 names 20 study sites across 11 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06188702 about?
NCT06188702 is a clinical study titled "S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP". This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatmen...
What is the current status of trial NCT06188702?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 342 participants. The study started on 2024-04-29. Estimated completion is 2031-10-31.
What conditions does trial NCT06188702 study?
This clinical trial studies the following conditions: MTAP-deleted Solid Tumors.
What interventions are being tested in trial NCT06188702?
The interventions under investigation include: S095035 (DRUG), TNG462 (DRUG).
Who is sponsoring clinical trial NCT06188702?
This trial is sponsored by Servier Bio-Innovation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06188702 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MTAP-deleted Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06188702's enrollment target sits among peer trials
342 103rd of 2000 higher than 1,898 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI